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ABSTRACT
The eDNA coding for the porcine pancreatic prophospholipase
A2 (proPLA) has been cloned and expressed in E. coli. Expression
of proPLA could only be obtained in the form of intracellular
aggregates after fusing the 15 kDa proPLA to a large (≥45 kDa)
bacterial peptide. The fusion protein was readily purified from
cell lysates. and specifically cleaved. Cleavage of the fusion
protein was achieved with either hydroxYlamine (at Asn/Gly
sequences in the denatured protein). or trypsin (between the
pro- and the mature PLA in the renatured fusion protein). The
former method releases a proPLA-like enzyme, while the latter
directly yields PLA. Renaturation of the fusion protein was made
possible by the use of a recently reported new S-sulphonation
method. The released (pro)PLA was purified (Yields of 2-3 mg/ltr
of culture medium), and showed identical properties compared to
native (pro)PLA.
INTRODUCTION
One of the major goals in today's biochemistry is the design
and construction of specifically tailored enzymes. Protein
engineering has proven an important tool in this respect, both
for the elucidation of the mechanisms that underly enzymatic
catalysis, as well as for the defined construction of altered
enzymes (see ref.1 for a review). However, the number of
(eukaryotic) enzymes subjected to protein engineering appears to
be somewhat small [1], as a result, probably, of two
limitations: (i) the enzyme's kinetics and three-dimensional (3-
D) structure should preferably be known in detail [1]; and (ii)
the enzyme should be amenable to genetic manipulation. which
includes expression of enzymatically active protein.
This latter factor seems to be the major cause for the
observed low numbers of enzyme engineering projects. A recent
review on the expression of eukaryotic proteins in E. c'oli [2]
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lists but 5 enzymes, out of a total of 33 eukaryotic proteins
expressed in the bacterial cytoplasm. Numerous other expression
systems, both prokaryotic and eukaryotic, have been developed
for the expression of biologically active proteins. Most of
these are designed to secrete the protein, in order to obtain
correct N-terminal residues. glycosylation and/or disulphide
bonds [2-5], which appear to be the major difficulties
associated with intracellular expression in E.coli [2] Some of
these systems have been used for protein engineering [6], but
none of them seems to equal E.coli yet in itS potential to
produce gram amounts of intracellular recombinant polypeptide
per liter of culture medium [2,7], in an easy and very rapid
way.
In order to carry out a protein engineering project of
lipolytic enzymes, we have devised and optimized an
intracellular expression system in E.coli. that conveniently
combines several published methods for: (i) purification of
insoluble fusion proteins from the cytoplasm [2], (ii) S-
sulphonation and subsequent reoxidation/renaturation of
recombinant proteins [8-10], and (iii) site specific cleavage of
fusion proteins with hydroxylamine [5,11], or enzymes, for the
liberation of the peptide of interest. We have used this system
for the expression of a pancreatic phospholipase A2
(EC.3,1.1.4., abbreviated PLA), because it is the only lipolytic
enzyme, that has been characterized to such detail [see ref.
12-14 for reviews] to allow for significant protein engineering
to be done. It is a small (14 kDa) stable protein, containIng
seven disulphide bridges, which is secreted by the pancreas as a
seven amino acid N-terminally extended proenzyme. In the
intestine this proenzyme is converted by trypsin to the active
enzyme [12], The 3-D structure is known to 1.7 and 2.3 A
resolution for the bovine and porcine enzymes respectivelY [13],
and extensive kinetic and sequence data are available for a
large number of very homologous enzymes from various species
[12] ,
In this report, we describe the cloning of cDNA, coding for
porcine proPLA, and subsequently the various possibilities of
our expression system, that lead to the rapid production of,
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either mature PLA, or proPLA [12]. Quantitative data are
presented for these methods. Milligram amounts of active PLA per
liter of culture medium, representing relative yields of about
30%, were readily obtained. We discuss the potential use of the
methodology for other heterologous proteins.
MATERIALS AND METHODS
Materials
All enzymes, oligo (dT), and oligo (dT)-cellulose were
purchased from Pharmacia and used according to the
manufacturer's instructions. β-Cyano-ethylphosphoramidite
nucleotides for oligonucleotide synthesis were from Biosyntech
(Hamburg, W-Germany). α35S-dATP was obtained from Amersham.
Guanidine hydrochloride and hydroxylamine were from Merck.
Immunochemicals and TPeK-trypsin were obtained from Sigma.
Synthetic phospholipids were kindly provided by R. Dijkman from
our laboratory.
Strains and plasmids
E.coli K-12 Strains HE101 [15], JM103 [16], and AB1157 [17],
have been described elswhere. pBR322 tailed with poly(dG) in the
PstI site, was bought from BRL. The pEX vector series was kindly
made available to us by Dr. K. Stanley [18]. Plasmid pCI857,
carrying the temperature sensitive A-repressor with a pACYC
origin was a gift of Dr. E. Remaut.
eDNA preparation and isolation of PLA clone
A fresh porcine pancreas was frozen and ground in a mortar
filled with liquid nitrogen, and subsequently lyophilized. From
the resulting fine powder, RNA was purified basically following
the procedure of Chirgwin et al. [19]. mRNA was enriched on a
poly(dT)-cellulose column according to Aviv and Leder [20], and
was checked for biological activity by translating 250 ng in a
wheat germ assay [21]. 35S-Labeled proteins were visualized by
SDS polyacrylamide gel electrophoresis [22] (SDS-PAGE) and
fluorography. mRNA of sufficient quality was then used to
prepare cDNA as described by Gubler and Hoffman [23]. The final
double stranded cDNA material was cloned into pBR322 by the
dC/dG tailing method. This material was used to transform
HBI01 [15] to tetracycline resistance. Ampicillin sensitive
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colonies were replica plated onto nitrocellulose filters and
screened for the presence of PLA coding sequences with the 32p_
labeled oligonucleotide mixture:
5'-ATGGA(T/C)TT(T/C)AA(T/C)AA(T/C)TA(T/C)GG-3' followIng
standard procedures [24]. Hybrid selected translation was used
to confirm the identity of the positive colonies [25]. The final
cDNA was sequenced with a set of progressive sequence primers,
synthesized by the phosphoramidite method (26]. The sequencing
method of Sänger et al. [27] was used either on M-13 single
stranded DNA, or on linearized double stranded DNA [28].
DNA techniques
Standard DNA operations were performed as described [29].
Unphosphorylated adaptor DNA molecules were ligated in a 100-
fold molar excess to the vector ends, followed by precipitation
with 0.1 volume of 5M sodium perchlorate and 0.5 volume of
isopropanol for 15 min at room temperature. The latter technique
ensures the complete removal of the excess unligated adaptor,
which might adversely affect transformation efficiencies. The
"adapted" ends were then phosphorylated and used for further
cloning experiments. We routinely isolated restriction fragments
from gel slices, using isotachophoresis [30].
Immunological techniques
PLA specific IgG was isolated from the serum of immunized
rabbits by passing the serum through a Sepharose CL-4B column to
which PLA had been covalently attached using CNBr [31]. Western
blotting was performed essentially as described by
Burnette [32]. Phospholipase-IgG complexes were visualised with
a second antibody, coupled to horse radish peroxidase (HRP).
Colony immuno-screening was done as follows: (i) colonies were
replica-plated onto nitrocellulose filters, either before, or
after induction of the expression plasmids; (ii) lysis of the
colonies was evoked by heating the filters on Whatman 3MM paper,
soaked in 2% SDS, in a microwave oven for 30 sec at 600 W,
followed by another 60 sec at 200 W; (iii) after precipitation
of the antigens with 10% TCA for 15 min at 4°C, the filters were
neutralized with 1M Tris and washed in saline; (iv) finally, the





The proenzyme is active on monomeric substrate only, and is
routinely assayed using dihexanoyl-dithio-phosphatidylcholine
(thio-diC6PC) as a substrate [33], Monomeric assay conditions
were: 0.5 mM thio-diC6PC, 50 mM Tris (pH 8), and 20 mM CaC12
with 0.1 mM dithionitrobenzoic acid (Ellman's reagent) The
enzymatic activity was continuously followed by recording the
absorbance at 412 nm. Specific activity of the porcine PLA under
these conditions is around 10 µmol.min-1.mg-1, enabling the
determination of less than 0.1 µg of proPLA.
The active enzyme (after activation of the proenzyme by
trypsin), is convenientlY assayed in the pH-stat [12], using
micellar L-dioctanoylphosphatidylcholine (L-diC8PC) as the
substrate. Micellar assay conditions were: 1 mM L-diC8PC, 1 mM
sodium borate (pH 8) and 15 mM CaC12 in a total volume of 2.5
ml. The fatty acids were titrated with 10 mM NaOH. In this
system, porcine PLA exhibits a specific activity of about 2000
µmol.min-1.mg-1, consequently, 0.2 µg of PLA can be easily
measured.
The renatured complete fusion protein was directly assayed
for its content of active PLA, by adding a portion to the
micellar assay reaction vessel, in which 10 µg of TPCK-trypsin
was included. Within 5 to 10 minutes the recorded acitivity was
linear with time, and this extrapolated value was compared to
the value obtained in the same manner with proPLA.
Recovery of (pro)PLA from isolated fusion proteins
Proteins were harvested from AB1157 harbouring pCI857, and
the appropriate expression plasmid, 3 hrs after the induction of
expression (by temperature shift). Protein aggregates were
isolated from cell lysates by a 30 min centrifugation at 5000xg
[34], and washed once with 0.1 % of Triton-X100.
PLA was recovered as follows. Fusion protein was sulphonated
at 2-5 mg/ml, as recently described by Tannhauser and Sheraga
[10]. The S-sulfo protein was precipitated by dialysis against
1% HAc, and the precipitate was washed several times with water.
Renaturation was induced by dissolving the protein, at 0.4
mg/ml, in 2 M Urea, 25 mM sodium borate (pH 8.5), 5 mM EDTA and
a mixture of 2 mM reduced- and 1 mM oxidized glutathione.
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Renaturation usuallY reached a maximal level after 24 hrs at
room temperature, as measured in the L-diC8PC assay. After
dialysis and concentration, preparative tryptic digestion of the
renatured fusion protein was done in a buffer containing: 1
mg/ml fusion protein, 20 mM Tris (pH 8). 15 mM CaCI2, and 1 mM
D-diC8PC. Trypsin (15 µg/ml) was added at intervals during a 2-3
hr incubation at room temperature, until the PLA activity had
reached a maximum. The mixture was then acidified to pH 5 and
centrifuged to remove the insoluble peptides. PLA was finally
purified on CM ion exchange resin, following established methods
[12] .
ProPLA was isolated from the fusion protein by cleavage with
hydroxylamine [11]. First, the inclusion bodies were solubilized
and reduced, at 5 mg/ml concentration, in 6 M GuanidIne, 50 mM
Tris (pH 8), 1 mM EDTA and 500 mM β-mercaptoethanol, for 1 hr
under N2. The mixture was then centrifuged and the supernatant
acidified with 1% HAc and dialyzed against 0.1 % HAc. The
precipitated fusion protein was washed twice with dilute acid,
and dissolved in 6 M Guanidine, 2 M hydroxylamine, adjusted to
pH 8.5 with LiOH, at a protein concentration of 5 mg/ml. After a
3½ hr incubation at 45 °C, the reaction was stopped by the
addition of ten volumes of 30 % HAc (V/V), and the resulting
peptide mixture was dialyzed against 1% HAc. Insoluble material
was removed by centrifugation and the soluble fraction was
adjusted to 1.5 M Guanidine, 50 mM Tris/HCl, 10 mM Ca2+ and 5 mM
CyS, pH 8,3 [35]. Following renaturation and dialysis, proPLA
activity could be directly measured.
RESULTS
Cloning and sequence of prophospholipase A2 encoding cDNA
mRNA from a fresh porcine pancreas was used for the
preparation of a cDNA bank in E. coli HB101. PLA specific clones
were identified and one of them (pPG4) was sequenced, as
described in Materials and Methods. It contained a 560 base
pairs (bp) long cDNA insert, covering the complete coding region
for the preproPLA. This coding region is shown in Fig 1. The
predicted amino acid sequence is in full agreement with the one




pol y - G GeT TTT GeT eAe eAA eeT GAe AGe AGG ATG AAA TTC
Met Lys Phe
-15
CTC GTG TTG GeT GTT eTG eTe AeA GTG 1GG00C GeT Gee▼eAG GAA GGe ATe AGe TeA AGG↓ GeA
Leu Val Leu Ala Val Leu Leu Thr Val Gly Ala Ala Gin Glu Gly Ile Ser Ser Arg Ala
-10 -1 I IT III III 11 111 VII 1
150
TTA TGG CAG TTTCGT AGC ATG ATT AAG TGC GCAATC CCC GGC AGT CAC CCC TTG ATG  GAT
Leu Trp GIn Phe Arg Ser Met lie Lys eyS Ala lIe Pra Gly Ser His Pra Leu Met Asp
10 20
200
TTC AAC AAC TAT GGC TGC TAC TGT GGC CTA GGT GGA TCA GGG ACC CCT GTG  GATGAA m
Phe Asn Asn Tyr Gly eyS Tyr eys Gly Leu Gly GlY Ser Gly Thr Pra Val Asp Glu Leu
30 40
250 300
GAC AGG TGC TGC GAG ACA CAC GAC AAC TGC TAC AGA  GATGCC AAG AAC mGAC AGC TGT 
Asp Arg CYs eyS Glu Thr His Asp Asn CyS Tyr Arg Asp Ala Lys Asn Leu Asp Ser eyS
50 00
350
AAA TTC CTC GTG GAC AAT CCC TAC ACC GAA AGC TAC TCC TAC TCA TGT TCT AAC ACT GAG
LyS Phe Leu Val Asp Asn Pra Tyr Thr Glu Ser Tyr Ser Tyr Ser eyS Ser Asn Thr Glu
70 00
400
ATC ACC TGC AAC AGC AAAAAC AAT GCT TGT GAGGCC TTCATC TGT AAC TGT GAC CGA AAT 
lie Thr CYS Asn Ser Lys Asn Asn Ala eyS Glu Ala Phe I Ie eyS Asn eyS Asp Arg Asn
00 100
GCT GCC ATT TGC TTC TCA AAG GCC CCA TAC AAC AAG GAGCAC AAG AAC mGAC ACC AAG
Ala Ala lie Cys Phe Ser Lys Ala Pro Tyr Asn Lys Glu HIs Lys Asn Leu Asp Thr Lys
no 120
500
AAG TAC TGT TAG AGe TAA GTA TeA ecc
Lys Tyr eyS *** ###
124
Fig 1. The DNA coding- and protein sequence of pig pancreatic
preprophospholipase A2. The solid triangle represents the
substrate site for signal peptidase. Roman numerals denote
residues of the activation peptide in proPLA, which is naturally
cleaved off by trypsin (arrow). The restriction map shows the
signal and the activation peptide as the hatched and open areas
respectively.
protein. we found a 15 amino acids N-terminal extension,
matching the criteria for a signal peptide as outlined by
Perlman and Halvorson (37]. Tnis tentative signal peptide is
also very homologous to the ones recently found in cloned PLA
eDNA's from rat and dog pancreas and human lung [38.39].
Furthermore, expression experiments in eukaryotic cell lines.
confirmed the functional integrity of this cDNA sequence, since
the proPLA was accurately processed into the culture medium
(P.de Geus, unpublished results) .
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Fig 2. Construction of cro/lacZ-proPLA expression vectors
with {Asn/GlY}3 linkage cassette (dotted box). The hatched area
represents the signal peptide. Residue numbering of proPLA
refers to Fig 1. Abbreviations: Sm. SmaI; Bm. BamHI; Sa. SaIl;
Ps, PstI; Ha, HaelI. The properties of the different vectors are
described in the text.
Expression of PLA eDNA in E.coli K-12
As it became evident that PLA could not be expressed to any
significant levels. either directly in the cytoplasm, or after
processing into the periplasmic space (data not shown), we
developed a strategy for the expression of PLA as a fusion
protein. This approach has led in several cases [2]. to the
succesful expression of eukaryotic proteins in E. coli, but
inevitably requires a cleavage step in the end. For this, we
intended to use the natural tryptic cleavage site, at the
junction of the propeptide and the native enzyme (cf. Fig.1)
The 560 bp cDNA fragment of pPG4 was cloned into the pEX
vector series, and clones were screened for the production of
PLA antigens by the colony immuno-screening method. One of
these, pPG402 (Fig 2), produced large quantities of the expected
130 kDa cro/lacZ-PLA fusion protein (Fig 3, lanes a and b).
Unfortunately, this protein, and also smaller deleted variants
3750
Nucleic Acids Research
Fig 3. SDS-PAGE of isolated inclusion bodies containing PLA
fusion protein, before and after hydroxylamine treatment. MS:
Molecular weight standard. Lane a: fusion protein from pPG402.
Lane c: hydroxylamine digest of a. Lane e: fusion protein from
pPG526. Lane g: hydroxylamine digest of e. Lanes b,d,f,h:
Western blots of respectively lanes a,c,e, and g, using anti-PLA
antibodies. Proteins were stained with fast green. The different
expression vectors are explained in the text.
(data not shown), could not be directly renatured nor cleaved by
trypsin, due to solubility problems. To overcome this problem,
we elaborated two independent alternative schemes: (i) chemical
cleavage under denaturing conditions, and (ii) chemical
modification to increase the solubility under renaturation
conditions, allowing subsequent cleavage by trypsin. The order
of individual steps, and protein folding stages, involved in
both routes is schematically outlined in Figure 4. It can be
seen in Fig.4 that by working out both routes the pro- as well
as the mature enzyme can be obtained and studied.
Recovery of proPLA from the fusion protein bY chemical cleavage
HydroxYlamine cleavage [11] of the peptide bond between Asn
and Gly residues (absent in PLA), was tested, a priori, on the
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Fig 4. Schematic representation of the different (folding)
stadia of the fusion protein during its processing into either
proPLA (left part) by hydroxYlamine cleavage, or PLA (right
part) by S-sulphonation/renaturation and trypsin
cleavage. --0: free -SH groups, : S-S bridges. ■
{Asn/GlY}3 linker. The arrow represents the cleavage site for
trypsin. GlyAlaAla-extended proPLA (the product of the NH20H
cleavage, arising from the location of the Asn/Gly linker in the
HaeII site of the PLA eDNA), is denoted by *PRO-PLA.
fusion protein from pPG402, for its general sequence
specificity. A digest of pPG402 protein (Fig 3 lane c) showed
distinct peptide fragments, in agreement with the locations of
the Asn-Gly sequences in the fusion protein. Besides the
expected 25 kDa, PLA containing peptide, partial (larger)
cleavage products can be seen in a Western blot (lane d),
indicating a less efficient cleavage reaction at some of the
Asn/Gly sites. The heavy band at the gel front is due to the
accumulation of small peptide fragments, resulting from the
aspecific cleavage by NH20H. Therefore, the complete procedure
was optimized, with respect to proPLA yields, by: (i) insertion
of a {Asn/GlY}3 linker sequence in the HaeII site, between
proPLA and the bacterial leader fragment of the fusion protein
(Fig 2, pPG502), and (ii) by deleting as much as possible of the
leader sequence, without affecting the final yield of fusion
3752
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Table I. Yields of (pro)PLA from fusion protein
produced by induction of 1 liter of E.coli
harbouring pPG526.
stage of total active
purification protein (pro)PLA
(mg) (mg)a
fusion protein ... 50 0
soluble peptides Hydroxylamine
after NH20H ... 10 0 cleavage
renatured peptides. 8 2.5
CM-ce llulose ... 2.3d 2.1
fusion protein ... 50 Ob
S-sulphonation ... 50 Ob Tryptic
renaturation ... 50 4.5b cleavage
trypsin cleavage ... -- 3.8c
CM-cellulose ... 3.1d 2.8c
The procedures and individual steps for the chemical and tryptic
cleavage of the fusion protein are described in the text
(cf.also Figure 4). Protein was estimated from SDS-PAGE. unless
otherwise noted. a:based on the activity in the thio-diC6PC
assay (see Materials and Methods). b:based on the activity in
the L-diC8PC assay including trypsin (see Materials and
Methods). c:based on the direct activity in the L-diC8PC assay,
after preparative scale tryptic digestion of the fusion protein.
d:based on the absorption at 280 nm.
protein too much. The resulting plasmid, pPG526 (Fig 2), upon
induction, produced a 59 kDa fusion protein up to about 2% of
total cellular protein, which could now be effectively digested
with hydroxylamine (Fig 3, lanes e-h). The peptide material thus
obtained from 1 ltr of cell culture, was renatured and the
activity of proPLA directly measured. The results are
summarized in Table I. It can be seen that the yield of active
proPLA is about 20 % of the theoretically possible yield (on the
basis of the molecular weight ratio: PLA/fused-PLA). The active
proPLA was purified on CM-cellulose in the same manner as is
described below for PLA.
Recovery of PLA from the fusion protein by tryptic cleavage
We found that the very rapid and mild S-sulphonation
procedure, recently described [10], rendered the fusion protein
from pPG526 soluble in renaturation buffer (see Materials and
Methods). After S-sulphonation and dialysis, the fusion protein
from 1 ltr of cell culture was dissolved in 8M Urea buffer, and
renaturation was started by dilution to 2M Urea with
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Fig 5. Purification of PLA after tryptic liberation of the
enzyme from fusion protein. Panel A shows the elution pattern of
a 10x2 em CM-cellulose column, at 4°C and pH 5,3 in 10 mM
acetate buffer, with a 2 x 100 ml salt gradient as indicated.
a.u.: arbitrary units. Panel B: The PLA fraction (hatched area)
was analyzed on the FPLC mono-S column (Pharmacia), using a 10
mM acetate buffer of pH 4.8. Panel C: SDS-PAGE of: lane 1,
molecular weight standard; lane 2. purified pancreatic PLA: lane
3, purified PLA from CM column in panel A.
concommittant addition of the glutathione redox couple. No
formation of a precipitate was observed during an overnight
stand at room temperature, nor thereafter, during the dialysis
against ammonium bicarbonate of pH 7.8. Thus, after
concentration, the renatured protein could be cut with trypsin
on a preparative scale, to yield the active PLA (30 % of
theoretical yield, see Table I), which could be directly
measured in the L-diC8PC assay. After acidification of the
reaction mixture a large precipitate formed, which did not
include the PLA. The supernatant obtained after this treatment
was loaded on a CM cellulose column at 4 °c and the proteins
were eluted with a salt gradient as indicated in Figure 5. The
PLA containing peak was collected and analyzed by FPLC mono-S,
and SDS-PAGE (Fig.5). It behaved in the same way as native PLA
purified from porcine pancreatic pancreas. The protein was
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judged to be over 90 % pure, and this was confirmed by comparing
the specific activity in the micellar assay (Table I). These
data show that we have produced authentic PLA from E. coli
derived fusion protein. Purification to near homogeneity is now
in progress with a scaled up procedure.
DISCUSSION
The porcine PLA cDNA clone isolated here, represents the more
predominant species of PLA isoenzymes found in pancreatic juice,
namely the one with Ala12, His17, Met20, and GlU71' rather than
Thr12, ASP17, Leu20, and Asn71 [40]. This is not surprising
since the oligonucleotide used in the initial screening, coded
for amino-acid Met20-GlY26. From the cDNA sequence it also
becomes clear that the pyroglutamic acid residue found at the N-
terminus of the natural proenzyme [12] must derive from
glutamine initially synthesized at that position. This
conversion can well have taken place in the secretory granules
of the pancreatic cells.
Several different approaches have been taken to express
proPLA in E. coli. Only when fused to a bacterial peptide could
PLA be expressed to sufficient amounts, as an insoluble
intracellular aggregate, which is not uncommon for eukaryotic
proteins in E. coli [2,7]. There are currently scarce
quantitative data on the necessary cleavage and renaturation
steps involved with fusion proteins [2], nor is there a general
methodology for solving these problems yet. In this report, we
describe two different methods, one chemical and one enzymatic,
for the site specific cleavage of the fusion protein. They were
chosen so as to enable the isolation of both a proenzyme-like-
and the active enzyme molecule (cf. Fig.4) Although the
chemical cleavage reaction yields GlyAlaAla- extended proPLA,
the enzymatic function is identical to that of native proPLA,
since the N-terminus does not playa functional role in the
proenzyme [12]. The markedly different properties [12] of both
enzyme species will be very helpful in the future for the
interpretation of the properties of engineered PLAses.
The chemical cleavage by hYdroxylamine is very convenient in
eliminating bacterial proteases in an early stage of the
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purification [cf ref.34]. The sequence specificity and yield
were high, provided that the {AsnGlY}3 linker was put in front
of proPLA. Therefore we think the method of general
applicability to those cases where no intrinsic AsnGly sequences
are present, and where either the N-terminus is not important
for biological activity, or can be subsequently removed by
another cleavage step.
Enzymatic cleavage methods of fusion proteins are clearly
highly desirable because of their mildness and potentially high
sequence specificity. The latter, however, tends to be displayed
only, in full, in non-denaturing buffers and on structurally
intact (folded) protein substrates. Fusion proteins, in most
cases, will be hard to solubilize, thus preventing refolding of
the passenger eukaryotic protein. We applied a new method of S-
sulphonation of cysteine residues [10], which eventually
overcomes this solubility problem by simultaneous removal of the
sulfo-groups (which solubilized the unfolded protein) and
promotion of S-S bridge formation (rendering the protein
soluble). It enabled us to produce active PLA within two days
following cell lysis, with a minimum of experimental work. The
method, therefore, is potentially very attractive for other
(cystein containing) proteins too, produced in E. coli.
The choice of proteolytic enzymes has been confined to a few
very specific ones [2]. For instance, Nagai and Thogersen [41]
were the first to use factor Xa for precise fusion protein
cleavage. It recognizes a tetrapeptide sequence and therefore is
claimed to be highly specific, even under denaturing conditions
[42]. But the enzyme is expensive and needs incubation times of
3 to 24 days [42]. Furthermore, as for all proteases, the
specificity is likely to depend also on the environment of the
target peptide in the fusion. Probably for these reasons.
Varadarajan et.al. used trypsin instead of factor Xa to release
myoglobin from a fusion protein, although the linkage was
through a Xa recognition sequence [7]. Also in the case of the
fused proPLA, tryptic cleavage was observed to be about 5-fold
slower than the comparable activation of native proPLA,
indicating effects of the environment on the accessibility of
the ArgVIIAla1 (Fig.1) bond.
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All of these data seem to argue that efforts in this field
should be directed towards the introduction, into fusion
proteins, of more highly labile peptidyl substrate bonds for
existing specific proteolytic enzymes. Positioned in fusion
proteins, these would then allow differential cleavage of fusion
proteins leaving the protein of interest intact, despite the
possible presence therein of other cleavage sites. In line with
this, we are presently constructing, in pPG526, a
ProVIArgVIIAla1 derivative of the PLA activation- peptide
sequence, which is known, in horse pancreatic PLA, to be
cleaved ten times faster than the corresponding site in the
porcine enzyme (this laboratory, unpublished results) .
We now have available a versatile set of expression tools
with which the engineering of (pro)PLA can be undertaken. The
methods described here could also be useful for the expression
as fusion protein in E. coli of other proteins rich in
disulphide bridges.
*To whom correspondence should be addressed
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